Reports Q1 revenue $13.8M, consensus $14.01M. “We delivered strong growth in revenue and shipments of ZURZUVAE during the first quarter of 2025 through the team’s disciplined execution and unwavering commitment to bringing ZURZUVAE to more women with postpartum depression,” said Barry Greene, Chief Executive Officer at Sage Therapeutics (SAGE). “We remain focused on establishing ZURZUVAE as the standard of care for women with postpartum depression and driving our business strategy forward with the goal of creating value for shareholders.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Is SAGE a Buy, Before Earnings?
- Cautious Outlook on SAGE Therapeutics: Hold Rating Maintained Amid EPS Adjustments and Revenue Forecast Revisions
- Cautious Outlook for SAGE Therapeutics Amid Strategic Uncertainty and Financial Challenges
- Sage Therapeutics resumed with an Underperform at BofA
- SAGE Therapeutics Announces CMO Resignation and Interim Appointment
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue